1. Home
  2. IDCC vs BLTE Comparison

IDCC vs BLTE Comparison

Compare IDCC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InterDigital Inc.

IDCC

InterDigital Inc.

HOLD

Current Price

$344.56

Market Cap

6.6B

Sector

Miscellaneous

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$163.05

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDCC
BLTE
Founded
1972
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
6.0B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
IDCC
BLTE
Price
$344.56
$163.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$412.50
$198.00
AVG Volume (30 Days)
251.5K
132.3K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
0.79%
N/A
EPS Growth
N/A
N/A
EPS
5.51
N/A
Revenue
$307,404,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.38
$492.11
P/E Ratio
$59.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$249.14
$60.00
52 Week High
$412.60
$200.00

Technical Indicators

Market Signals
Indicator
IDCC
BLTE
Relative Strength Index (RSI) 76.89 57.68
Support Level $315.71 $153.54
Resistance Level $336.25 $161.17
Average True Range (ATR) 10.92 5.93
MACD 8.07 0.23
Stochastic Oscillator 90.82 81.36

Price Performance

Historical Comparison
IDCC
BLTE

About IDCC InterDigital Inc.

InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: